The decision to switch should always involve a detailed conversation with your healthcare provider to understand the pros and cons
Tirzepatide/Mounjaro already has FDA approval for diabetes, and it now has two global phase 3 clinical trials supporting its potential for weight loss, following even stronger SURMOUNT-1 results among non-diabetic patients (up to 22% weight loss)
To examine this phenomenon more closely, we divided the feeding behavior into 3 stages (initial, middle, and final) and observed a gradually diminishing inhibitory response from the initial to the final stage (Figure 4, K and L)
Is Off-Label Ozempic Use for Weight Loss Dangerous
This article examines the safety profile of GLP-1 medicines for breast cancer survivors, reviews current research, and provides guidance on discussing treatment options with your healthcare team